Real estate for dentists: building ownership + personal portfolio

Optimizing the Practice Sale: Tax Structuring for a PE Buyout

Private equity’s interest in dentistry isn’t new, but the pace of consolidation is accelerating. If you’re a practice owner, a potential buyout is a question of “when,” not “if.” The headline price is exciting, but the number that matters is what you keep after taxes. And that is determined almost entirely by the deal structure you negotiate.

When a PE firm buys your practice, they can structure it as either an asset sale or a stock sale. The buyer almost always wants an asset sale; the seller should almost always demand a stock sale.

Here’s why. In an asset sale, the PE firm is buying the individual assets of your practice—chairs, computers, patient lists (goodwill), and accounts receivable. The IRS treats the sale of each asset class differently. Your equipment, for which you’ve been taking depreciation deductions for years, will be subject to “depreciation recapture,” taxed at high ordinary income rates (up to 37%). Your accounts receivable are also taxed as ordinary income. Only the goodwill component typically qualifies for the lower long-term capital gains (LTCG) rate (currently 15-20%). The result is a blended, and often painfully high, effective tax rate.

In a stock sale, the buyer purchases the shares of your S-Corp or C-Corp directly. The transaction is clean. For you, the seller, the entire gain is typically treated as a long-term capital gain, assuming you’ve owned the practice for more than a year. The difference between paying a 20% LTCG rate versus a 37% ordinary income rate on a multi-million dollar sale can easily be hundreds of thousands of dollars.

The Trap to Avoid: The most common mistake is focusing solely on the purchase price. A $5 million asset sale could easily leave you with less after-tax cash than a $4.5 million stock sale. When a buyer insists on an asset sale (often for their own tax benefit of being able to re-depreciate the assets), your response shouldn’t be “no,” but rather, “You need to make me whole.” This means negotiating a higher purchase price—a “tax gross-up”—to compensate for your higher tax liability. Model this out with a CPA who understands healthcare M&A. Don’t leave seven figures on the table by ignoring the tax structure.

Equity Rollover: The Art of Staying in the Game

In many PE buyouts, the deal isn’t 100% cash. A common structure involves taking a significant portion of your payment in the form of equity in the new, larger parent company. This is called “rollover equity,” and it’s a powerful tool if you understand the mechanics.

Let’s say your practice is valued at $4 million. The PE firm might offer you $3.2 million in cash (80%) and $800,000 in rollover equity (20%). The immediate, massive benefit is tax deferral. You pay capital gains tax now on the $3.2 million cash portion, but you pay zero tax on the $800,000 of equity you’ve rolled over. That tax liability is deferred until a future liquidity event—what’s often called the “second bite of the apple.” This happens when the PE firm sells the entire consolidated platform to another, larger firm or takes it public, typically 5-7 years down the line.

If the new platform grows and its valuation increases, your $800,000 stake could be worth $1.6 million, $2.4 million, or more. You get to participate in the upside you helped create. This aligns your incentives with the new owner and can be far more lucrative than a pure cash deal.

The How-To Sequence:

1. Negotiate the Split: The cash-to-equity ratio is a key negotiation point. More cash means less risk; more equity means more potential upside. Your risk tolerance and confidence in the PE firm’s plan should guide this decision.
2. Vet the Partner: You are becoming a minority investor in their company. Perform due diligence on the PE firm. What is their track record with other dental practices? What is their strategic plan for growth? Who is on the management team?
3. Understand the Terms: Your rollover equity will come with strings attached. Scrutinize the shareholders’ agreement. What are your rights? Are you subject to drag-along provisions? What are the restrictions on selling your shares?

The Trap to Avoid: Getting blinded by the potential upside without realistically assessing the risk. Rollover equity is illiquid and not guaranteed to grow. If the new platform underperforms, your equity could be worth less than you rolled in, or even zero. You’ve traded a certain cash payment for a speculative future one. Ensure you take enough cash off the table in the initial sale to secure your financial independence, regardless of what happens to the rollover.

The Hidden Tax Credit: R&D for Your In-House Innovations

When clinicians hear “Research & Development (R&D) tax credit,” they think of software companies or biotech labs. Most have no idea that the clinical problem-solving they do every day can qualify. Under Internal Revenue Code §41, businesses that develop new or improved products, processes, or software can receive a significant tax credit. For a dental practice, this is a massively overlooked opportunity.

What qualifies? The IRS uses a four-part test, but in practical terms for a dentist, it looks like this:

• Developing Custom Appliances: Are you using 3D printing and new materials to create a better surgical guide, a more effective sleep apnea device, or a novel orthodontic appliance? The process of iterating on designs, testing materials, and documenting outcomes is R&D.
• Improving Clinical Processes: Have you developed a new, proprietary technique for bone grafting or implant placement? If you are systematically experimenting to create a more efficient or effective clinical protocol, the time your staff spends on this can qualify.
• Building Internal Software: Did you hire a developer to build a custom module for your practice management software to better track implant integration or perio outcomes? The wages and contractor fees associated with this development are qualifying expenses.

The credit is calculated based on your “Qualified Research Expenses” (QREs), which primarily include the wages of employees involved in the R&D, the cost of supplies consumed during the process, and a portion of payments to outside contractors. This can translate into a dollar-for-dollar reduction of your tax bill, often worth tens of thousands of dollars annually.

The Trap to Avoid: Lack of documentation. You cannot simply decide at the end of the year that you did some R&D. The IRS requires you to have contemporaneous documentation that proves you were engaged in a “process of experimentation.” This means keeping records of your hypotheses, your tests, your failures, and your successful results. Project notes, lab logs, and even dated emails can serve as proof. Without a paper trail, the credit is indefensible on audit.

Valuation and EBITDA: Speaking the Language of Private Equity

To optimize your practice for a potential sale, you have to understand how a financial buyer values it. They don’t care about your beautiful office design or how much you love your patients. They care about one primary metric: EBITDA. This stands for Earnings Before Interest, Taxes, Depreciation, and Amortization, and it’s the cleanest measure of your practice’s raw profitability and cash flow.

A PE firm will determine your practice’s value by applying a “multiple” to your EBITDA. For example, if your practice generates $500,000 in annual EBITDA and the going rate for a practice of your size and specialty is an 8x multiple, your valuation is $4 million ($500,000 x 8).

Your entire focus in the 2-3 years leading up to a sale should be on maximizing both your EBITDA and the multiple a buyer is willing to pay.

• To Increase EBITDA: This is about operational efficiency. Control overhead, optimize staff scheduling, improve collection rates, and strategically add higher-margin procedures. Every dollar you add to the bottom line is multiplied by 6x, 8x, or even 10x in the sale price.
• To Increase the Multiple: This is about de-risking the business for the buyer. A practice that is highly dependent on the owner-dentist will get a lower multiple. Factors that drive multiples higher include: having multiple associate dentists with low turnover, strong recurring revenue from hygiene and membership plans, modern facilities with up-to-date equipment, and a dominant market share in your geography.

When you’re looking at market trends, you can find high-level comps and analysis from sources like Repit housing data and other financial market aggregators to get a sense of where multiples are heading, though healthcare-specific data is often held by boutique investment banks.

The Trap to Avoid: Making capital expenditures that don’t increase EBITDA. Buying a brand new $150,000 CBCT machine a year before you sell might feel like you’re improving the practice, but it’s a mistake. That purchase will be added back to calculate EBITDA, so it doesn’t increase your earnings number. And the buyer was likely planning to upgrade equipment anyway. You’ve spent cash that you won’t see a return on in the valuation. In the years before a sale, every decision should be filtered through the lens of: “Does this increase EBITDA or my multiple?”

Unlocking Hidden Value in Your Building: Cost Segregation Studies

If you own your practice building, you’re likely leaving a massive amount of money on the table through suboptimal depreciation. When you buy a commercial property, the IRS typically makes you depreciate the value of the building over a 39-year straight-line schedule. But a building isn’t just one thing; it’s a collection of different components, many of which have a much shorter useful life than the structure itself.

This is where a cost segregation study comes in. It’s a detailed engineering analysis that identifies and reclassifies building components into shorter depreciation categories.

• 39-Year Property: The core structure of the building (foundation, walls, roof).
• 15-Year Property: Land improvements like parking lots, landscaping, and exterior signage.
• 7-Year Property: Office furniture and fixtures.
• 5-Year Property: Carpeting, decorative lighting, cabinetry, and specialty electrical or plumbing for dental equipment.

By reclassifying, say, 25% of a $1.5 million building’s cost from a 39-year life to a 5- and 7-year life, you can dramatically accelerate your depreciation deductions. Instead of small deductions spread over four decades, you get huge deductions in the first few years of ownership. Thanks to bonus depreciation rules (which are currently phasing down from 100% but still substantial), you can often deduct the entire cost of these reclassified 5-, 7-, and 15-year assets in the very first year.

This creates a massive “paper loss” that can offset your other active income. For a high-income dentist, a cost segregation study on a newly acquired building or one purchased years ago (you can do a look-back study) can generate a six-figure tax deduction in a single year. You can model out the potential return on a property using a real estate investing calculator that accounts for these advanced depreciation strategies.

The Trap to Avoid: Thinking it’s a DIY project. A cost segregation study must be performed by a qualified engineering firm that specializes in this work. It’s not something your regular CPA can just estimate. A properly executed study is defensible under IRS audit and is the key to unlocking this powerful tax strategy for your practice real estate and any other investment properties you own.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 7, 2026